{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:40:19Z","timestamp":1790707219631,"version":"4.1.0"},"reference-count":73,"publisher":"Impact Journals, LLC","issue":"66","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,12,15]]},"DOI":"10.18632\/oncotarget.22454","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T18:47:30Z","timestamp":1512672450000},"page":"110016-110028","source":"Crossref","is-referenced-by-count":19,"title":["HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells"],"prefix":"10.18632","volume":"8","author":[{"given":"Eva","family":"Juengel","sequence":"first","affiliation":[{"name":"Department of Urology, Goethe-University, Frankfurt am Main, Germany"},{"name":"Current address: Department of Urology and Pediatric Urology, Mainz University Medical Center, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Najafi","sequence":"additional","affiliation":[{"name":"Department of Urology, Goethe-University, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Rutz","sequence":"additional","affiliation":[{"name":"Department of Urology, Goethe-University, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Maxeiner","sequence":"additional","affiliation":[{"name":"Department of Urology, Goethe-University, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Makarevic","sequence":"additional","affiliation":[{"name":"Department of Urology, Goethe-University, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Roos","sequence":"additional","affiliation":[{"name":"Department of Urology, Goethe-University, Frankfurt am Main, Germany"},{"name":"Current address: Department of Urology and Pediatric Urology, Mainz University Medical Center, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Tsaur","sequence":"additional","affiliation":[{"name":"Department of Urology, Goethe-University, Frankfurt am Main, Germany"},{"name":"Current address: Department of Urology and Pediatric Urology, Mainz University Medical Center, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Haferkamp","sequence":"additional","affiliation":[{"name":"Department of Urology, Goethe-University, Frankfurt am Main, Germany"},{"name":"Current address: Department of Urology and Pediatric Urology, Mainz University Medical Center, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman A.","family":"Blaheta","sequence":"additional","affiliation":[{"name":"Department of Urology, Goethe-University, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,11,6]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Jemal","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"2","volume-title":"Cancer Facts & Figures","author":"American Cancer Society","year":"2016"},{"key":"3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ctrv.2016.09.018","article-title":"Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope","volume":"50","author":"Carles","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"4","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Bray","year":"2015","journal-title":"Int J Cancer"},{"key":"5","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.2147\/DDDT.S112113","article-title":"Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer","volume":"10","author":"Cekanova","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"6","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2012.46.5740","article-title":"Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer","volume":"31","author":"Garcia-Grossman","year":"2013","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4111\/kju.2011.52.7.466","article-title":"Role of the mTOR Pathway in the Progression and Recurrence of Bladder Cancer: An Immunohistochemical Tissue Microarray Study","volume":"52","author":"Chang","year":"2011","journal-title":"Korean J Urol"},{"key":"8","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/j.1365-2559.2011.03856.x","article-title":"Activation of the PI3K\/Akt\/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder","volume":"58","author":"Pan","year":"2011","journal-title":"Histopathology"},{"key":"9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"10","doi-asserted-by":"crossref","first-page":"11541","DOI":"10.1007\/s13277-016-5083-1","article-title":"mTOR inhibitors in urinary bladder cancer","volume":"37","author":"Santos","year":"2016","journal-title":"Tumour Biol"},{"key":"11","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1093\/annonc\/mds057","article-title":"Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers","volume":"23","author":"Verhoeven","year":"2012","journal-title":"Ann Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.urolonc.2016.12.002","article-title":"Strategies to overcome therapeutic resistance in renal cell carcinoma","volume":"35","author":"Haake","year":"2017","journal-title":"Urol Oncol"},{"key":"13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10585-011-9386-8","article-title":"Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells","volume":"28","author":"Blaheta","year":"2011","journal-title":"Clin Exp Metastasis"},{"key":"14","doi-asserted-by":"publisher","first-page":"85208","DOI":"10.18632\/oncotarget.13421","article-title":"Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro","volume":"7","author":"Blaheta","year":"2016","journal-title":"Oncotarget"},{"key":"15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1476-4598-13-152","article-title":"HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A","volume":"13","author":"Blaheta","year":"2014","journal-title":"Mol Cancer"},{"key":"16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.canlet.2012.05.003","article-title":"Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells","volume":"324","author":"Blaheta","year":"2012","journal-title":"Cancer Lett"},{"key":"17","doi-asserted-by":"crossref","first-page":"16041","DOI":"10.1038\/cddiscovery.2016.41","article-title":"An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers","volume":"2","author":"Huang","year":"2016","journal-title":"Cell Death Discov"},{"key":"18","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1158\/1078-0432.CCR-12-0055","article-title":"Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling","volume":"18","author":"DellaRocca","year":"2012","journal-title":"Clin Cancer Res"},{"key":"19","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.18632\/oncotarget.2992","article-title":"mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells","volume":"6","author":"Fruman","year":"2015","journal-title":"Oncotarget"},{"key":"20","doi-asserted-by":"publisher","first-page":"16367","DOI":"10.18632\/oncotarget.14829","article-title":"The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib\/dabrafenib-resistant melanoma cells in vitro and in vivo","volume":"8","author":"Dent","year":"2017","journal-title":"Oncotarget"},{"key":"21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1586\/erm.09.8","article-title":"mTOR in renal cell cancer: modulator of tumor biology and therapeutic target","volume":"9","author":"Wysocki","year":"2009","journal-title":"Expert Rev Mol Diagn"},{"key":"22","doi-asserted-by":"publisher","first-page":"8974","DOI":"10.18632\/oncotarget.3291","article-title":"GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth","volume":"6","author":"Sun","year":"2015","journal-title":"Oncotarget"},{"key":"23","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/jcmm.13091","article-title":"Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1\/cyclin axis","volume":"21","author":"Liang","year":"2017","journal-title":"J Cell Mol Med"},{"key":"24","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s12253-016-0075-4","article-title":"p21 and p27 Immunoexpression in Upper Urinary Tract Urothelial Carcinomas","volume":"22","author":"Sen","year":"2016","journal-title":"Pathol Oncol Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.humpath.2015.06.003","article-title":"Immunoprofile-based subgrouping of urothelial bladder carcinomas for survival prediction","volume":"46","author":"Cho","year":"2015","journal-title":"Hum Pathol"},{"key":"26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.eururo.2013.03.043","article-title":"Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy","volume":"64","author":"Shariat","year":"2013","journal-title":"Eur Urol"},{"key":"27","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1158\/1541-7786.MCR-16-0111","article-title":"AMPK\u03b12 Regulates Bladder Cancer Growth through SKP2-Mediated Degradation of p27","volume":"14","author":"Claffey","year":"2016","journal-title":"Mol Cancer Res"},{"key":"28","doi-asserted-by":"publisher","first-page":"27511","DOI":"10.18632\/oncotarget.8484","article-title":"Crosstalk between the IGF-1R\/AKT\/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor","volume":"7","author":"Maki","year":"2016","journal-title":"Oncotarget"},{"key":"29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1089\/cbr.2014.1697","article-title":"TRPM2 mediates histone deacetylase inhibition-induced apoptosis in bladder cancer cells","volume":"30","author":"Shen","year":"2015","journal-title":"Cancer Biother Radiopharm"},{"key":"30","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/CAD.0b013e32834a2c70","article-title":"HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro","volume":"22","author":"Blaheta","year":"2011","journal-title":"Anticancer Drugs"},{"key":"31","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/1535370213498975","article-title":"HDAC inhibition suppresses bladder cancer cell adhesion to collagen under flow conditions","volume":"238","author":"Blaheta","year":"2013","journal-title":"Exp Biol Med (Maywood)"},{"key":"32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1756-8722-4-17","article-title":"Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer","volume":"4","author":"Wang","year":"2011","journal-title":"J Hematol Oncol"},{"key":"33","doi-asserted-by":"crossref","first-page":"e106206","DOI":"10.1371\/journal.pone.0106206","article-title":"Tetramethoxychalcone, a chalcone derivative, suppresses proliferation, blocks cell cycle progression, and induces apoptosis of human ovarian cancer cells","volume":"9","author":"Yang","year":"2014","journal-title":"PLoS One"},{"key":"34","first-page":"294","article-title":"Histone deacetylase inhibitor reverses multidrug resistance by attenuating the nucleophosmin level through PI3K\/Akt pathway in breast cancer","volume":"49","author":"Dong","year":"2016","journal-title":"Oncol"},{"key":"35","doi-asserted-by":"crossref","first-page":"e2063","DOI":"10.1038\/cddis.2015.328","article-title":"Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms","volume":"7","author":"Wu","year":"2016","journal-title":"Cell Death Dis"},{"key":"36","doi-asserted-by":"crossref","first-page":"41615","DOI":"10.1038\/srep41615","article-title":"A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance","volume":"7","author":"Song","year":"2017","journal-title":"Sci Rep"},{"key":"37","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1007\/s11064-016-2043-5","article-title":"Histone Deacetylase Inhibitor RGFP109 Overcomes Temozolomide Resistance by Blocking NF-\u03baB-Dependent Transcription in Glioblastoma Cell Lines","volume":"41","author":"Li","year":"2016","journal-title":"Neurochem Res"},{"key":"38","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.tranon.2016.08.007","article-title":"Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma","volume":"9","author":"Wang","year":"2016","journal-title":"Transl Oncol"},{"key":"39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13058-016-0676-6","article-title":"Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer","volume":"18","author":"Spears","year":"2016","journal-title":"Breast Cancer Res"},{"key":"40","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1158\/1078-0432.CCR-16-2271","article-title":"Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer","volume":"23","author":"Yano","year":"2017","journal-title":"Clin Cancer Res"},{"key":"41","doi-asserted-by":"crossref","first-page":"35","DOI":"10.21873\/anticanres.11286","article-title":"Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer","volume":"37","author":"Perrea","year":"2017","journal-title":"Anticancer Res"},{"key":"42","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1200\/JCO.2012.43.7251","article-title":"Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor","volume":"31","author":"Trepel","year":"2013","journal-title":"J Clin Oncol"},{"key":"43","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/bjc.2011.156","article-title":"A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer","volume":"104","author":"Minton","year":"2011","journal-title":"Br J Cancer"},{"key":"44","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s10637-015-0261-3","article-title":"Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors","volume":"33","author":"Plimack","year":"2015","journal-title":"Invest New Drugs"},{"key":"45","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.3892\/etm.2016.3907","article-title":"Anticancer effects of valproic acid on oral squamous cell carcinoma via SUMOylation in vivo and in vitro","volume":"12","author":"Yu","year":"2016","journal-title":"Exp Ther Med"},{"key":"46","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1002\/cncr.20709","article-title":"Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis","volume":"101","author":"Koeffler","year":"2004","journal-title":"Cancer"},{"key":"47","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/1078-0432.CCR-03-0100","article-title":"Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells","volume":"10","author":"Koeffler","year":"2004","journal-title":"Clin Cancer Res"},{"key":"48","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1111\/jcmm.12583","article-title":"Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells","volume":"19","author":"Blaheta","year":"2015","journal-title":"J Cell Mol Med"},{"key":"49","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/j.1582-4934.2008.00436.x","article-title":"The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo","volume":"13","author":"Blaheta","year":"2009","journal-title":"J Cell Mol Med"},{"key":"50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12967-016-0801-4","article-title":"C14orf166 is a high-risk biomarker for bladder cancer and promotes bladder cancer cell proliferation","volume":"14","author":"Qin","year":"2016","journal-title":"J Transl Med"},{"key":"51","doi-asserted-by":"publisher","first-page":"32177","DOI":"10.18632\/oncotarget.4867","article-title":"GOLPH3 is a potential therapeutic target and a prognostic indicator of poor survival in bladder cancer treated by cystectomy","volume":"6","author":"Guo","year":"2015","journal-title":"Oncotarget"},{"key":"52","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.humpath.2012.11.026","article-title":"Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer","volume":"44","author":"Kassouf","year":"2013","journal-title":"Hum Pathol"},{"key":"53","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1309\/AJCP76KUVOTBKQRY","article-title":"Primary adenocarcinoma of the urinary bladder: value of cell cycle biomarkers","volume":"135","author":"Youssef","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jnutbio.2016.10.019","article-title":"A naturally occurring mixture of tocotrienols inhibits the growth of human prostate tumor, associated with epigenetic modifications of cyclin-dependent kinase inhibitors p21 and p27","volume":"40","author":"Kong","year":"2017","journal-title":"J Nutr Biochem"},{"key":"55","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.canlet.2012.07.032","article-title":"Helicobacter pylori decreases p27 expression through the delta opioid receptor-mediated inhibition of histone acetylation within the p27 promoter","volume":"326","author":"Kim","year":"2012","journal-title":"Cancer Lett"},{"key":"56","first-page":"105","article-title":"Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells","volume":"28","author":"Tsubura","year":"2012","journal-title":"Oncol Rep"},{"key":"57","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2184.2012.00812.x","article-title":"Sox2 targets cyclinE, p27 and survivin to regulate androgen-independent human prostate cancer cell proliferation and apoptosis","volume":"45","author":"Yu","year":"2012","journal-title":"Cell Prolif"},{"key":"58","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/his.12499","article-title":"Cyclin A1 expression predicts progression in pT1 urothelial carcinoma of bladder: a tissue microarray study of 149 patients treated by transurethral resection","volume":"66","author":"Netto","year":"2015","journal-title":"Histopathology"},{"key":"59","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1186\/1471-2407-12-611","article-title":"HuR cytoplasmic expression is associated with increased cyclin A expression and poor outcome with upper urinary tract urothelial carcinoma","volume":"12","author":"Chen","year":"2012","journal-title":"BMC Cancer"},{"key":"60","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.4161\/cc.19882","article-title":"Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer","volume":"11","author":"Keyomarsi","year":"2012","journal-title":"Cell Cycle"},{"key":"61","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/mnfr.201000096","article-title":"Gallic acid induces G2\/M phase cell cycle arrest via regulating 14-3-3\u03b2 release from Cdc25C and Chk2 activation in human bladder transitional carcinoma cells","volume":"54","author":"Lee","year":"2010","journal-title":"Mol Nutr Food Res"},{"key":"62","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Weinberg","year":"2011","journal-title":"Cell"},{"key":"63","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.02.008","article-title":"Inhibitors of cyclin-dependent kinases as cancer therapeutics","volume":"173","author":"Clarke","year":"2017","journal-title":"Pharmacol Ther"},{"key":"64","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3892\/ol.2013.1565","article-title":"Inhibitory effect of valproic acid on bladder cancer in combination with chemotherapeutic agents in vitro and in vivo","volume":"6","author":"Tian","year":"2013","journal-title":"Oncol Lett"},{"key":"65","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3892\/ol.2016.4880","article-title":"Valproic acid induces autophagy by suppressing the Akt\/mTOR pathway in human prostate cancer cells","volume":"12","author":"Jin","year":"2016","journal-title":"Oncol Lett"},{"key":"66","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40478-015-0184-4","article-title":"Decreased mTOR signaling pathway in human idiopathic autism and in rats exposed to valproic acid","volume":"3","author":"Fahnestock","year":"2015","journal-title":"Acta Neuropathol Commun"},{"key":"67","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mcn.2016.06.004","article-title":"Valproic acid exposure sequentially activates Wnt and mTOR pathways in rats","volume":"75","author":"Yin","year":"2016","journal-title":"Mol Cell Neurosci"},{"key":"68","doi-asserted-by":"crossref","first-page":"e53100","DOI":"10.1371\/journal.pone.0053100","article-title":"Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo","volume":"8","author":"Blaheta","year":"2013","journal-title":"PLoS One"},{"key":"69","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/jcmm.12299","article-title":"Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells","volume":"18","author":"Blaheta","year":"2014","journal-title":"J Cell Mol Med"},{"key":"70","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1158\/1078-0432.CCR-14-2055","article-title":"Team work matters: dual inhibition puts non-hodgkin lymphoma under siege","volume":"20","author":"Ghobrial","year":"2014","journal-title":"Clin Cancer Res"},{"key":"71","doi-asserted-by":"publisher","first-page":"67521","DOI":"10.18632\/oncotarget.11750","article-title":"Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy","volume":"7","author":"Patel","year":"2016","journal-title":"Oncotarget"},{"key":"72","doi-asserted-by":"publisher","first-page":"60169","DOI":"10.18632\/oncotarget.11109","article-title":"Superior efficacy of co-treatment with the dual PI3K\/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC","volume":"7","author":"Lin","year":"2016","journal-title":"Oncotarget"},{"key":"73","first-page":"290368","article-title":"The HDAC inhibitor Vorinostat diminishes the in vitro metastatic behavior of Osteosarcoma cells","volume":"2015","author":"Weiss","year":"2015","journal-title":"Biomed Res Int"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.22454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T01:37:57Z","timestamp":1660095477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.22454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,6]]},"references-count":73,"journal-issue":{"issue":"66","published-print":{"date-parts":[[2017,12,15]]}},"alternative-id":["22454","29299126"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.22454","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,6]]}}}